BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 36940407)

  • 1. Isolated Hepatic Perfusion With Melphalan for Patients With Isolated Uveal Melanoma Liver Metastases: A Multicenter, Randomized, Open-Label, Phase III Trial (the SCANDIUM Trial).
    Olofsson Bagge R; Nelson A; Shafazand A; All-Eriksson C; Cahlin C; Elander N; Helgadottir H; Kiilgaard JF; Kinhult S; Ljuslinder I; Mattsson J; Rizell M; Sternby Eilard M; Ullenhag GJ; Nilsson JA; Ny L; Lindnér P
    J Clin Oncol; 2023 Jun; 41(16):3042-3050. PubMed ID: 36940407
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Survival and Quality of Life after Isolated Hepatic Perfusion with Melphalan as a Treatment for Uveal Melanoma Liver Metastases - Final Results from the Phase III Randomized Controlled Trial SCANDIUM.
    Olofsson Bagge R; Nelson A; Shafazand A; All-Eriksson C; Cahlin C; Elander N; Gustavsson A; Helgadottir H; Kiilgaard JF; Kinhult S; Ljuslinder I; Mattsson J; Rizell M; Sternby Eilard M; Ullenhag GJ; Nilsson JA; Ny L; Lindnér P
    Ann Surg; 2024 Feb; ():. PubMed ID: 38420778
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Isolated hepatic perfusion for ocular melanoma metastasis: registry data suggests a survival benefit.
    Olofsson R; Cahlin C; All-Ericsson C; Hashimi F; Mattsson J; Rizell M; Lindnér P
    Ann Surg Oncol; 2014 Feb; 21(2):466-72. PubMed ID: 24141377
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Isolated hepatic perfusion as a treatment for uveal melanoma liver metastases (the SCANDIUM trial): study protocol for a randomized controlled trial.
    Olofsson R; Ny L; Eilard MS; Rizell M; Cahlin C; Stierner U; Lönn U; Hansson J; Ljuslinder I; Lundgren L; Ullenhag G; Kiilgaard JF; Nilsson J; Lindnér P
    Trials; 2014 Aug; 15():317. PubMed ID: 25106493
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Isolated hepatic perfusion with high-dose melphalan for the treatment of uveal melanoma metastases confined to the liver.
    Noter SL; Rothbarth J; Pijl ME; Keunen JE; Hartgrink HH; Tijl FG; Kuppen PJ; van de Velde CJ; Tollenaar RA
    Melanoma Res; 2004 Feb; 14(1):67-72. PubMed ID: 15091197
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Isolated hepatic perfusion for unresectable hepatic metastases from colorectal cancer.
    Bartlett DL; Libutti SK; Figg WD; Fraker DL; Alexander HR
    Surgery; 2001 Feb; 129(2):176-87. PubMed ID: 11174711
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Isolated hepatic perfusion with oxaliplatin combined with 100 mg melphalan in patients with metastases confined to the liver: A phase I study.
    van Iersel LB; de Leede EM; Vahrmeijer AL; Tijl FG; den Hartigh J; Kuppen PJ; Hartgrink HH; Gelderblom H; Nortier JW; Tollenaar RA; van de Velde CJ
    Eur J Surg Oncol; 2014 Nov; 40(11):1557-63. PubMed ID: 25125340
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Percutaneous Isolated Hepatic Perfusion as a Treatment for Isolated Hepatic Metastases of Uveal Melanoma: Patient Outcome and Safety in a Multi-centre Study.
    Vogl TJ; Koch SA; Lotz G; Gebauer B; Willinek W; Engelke C; Brüning R; Zeile M; Wacker F; Vogel A; Radeleff B; Scholtz JE
    Cardiovasc Intervent Radiol; 2017 Jun; 40(6):864-872. PubMed ID: 28144756
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Management of isolated nonresectable liver metastases in colorectal cancer patients: a case-control study of isolated hepatic perfusion with melphalan versus systemic chemotherapy.
    van Iersel LBJ; Koopman M; van de Velde CJH; Mol L; van Persijn van Meerten EL; Hartgrink HH; Kuppen PJK; Vahrmeijer AL; Nortier JWR; Tollenaar RAEM; Punt C; Gelderblom H
    Ann Oncol; 2010 Aug; 21(8):1662-1667. PubMed ID: 20110289
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Isolated hepatic perfusion for the treatment of patients with colorectal cancer liver metastases after irinotecan-based therapy.
    Alexander HR; Libutti SK; Pingpank JF; Bartlett DL; Helsabeck C; Beresneva T
    Ann Surg Oncol; 2005 Feb; 12(2):138-44. PubMed ID: 15827794
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Results of a Randomized Controlled Multicenter Phase III Trial of Percutaneous Hepatic Perfusion Compared with Best Available Care for Patients with Melanoma Liver Metastases.
    Hughes MS; Zager J; Faries M; Alexander HR; Royal RE; Wood B; Choi J; McCluskey K; Whitman E; Agarwala S; Siskin G; Nutting C; Toomey MA; Webb C; Beresnev T; Pingpank JF
    Ann Surg Oncol; 2016 Apr; 23(4):1309-19. PubMed ID: 26597368
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Meta-Analysis of Isolated Hepatic Perfusion and Percutaneous Hepatic Perfusion as a Treatment for Uveal Melanoma Liver Metastases.
    Bethlehem MS; Katsarelias D; Olofsson Bagge R
    Cancers (Basel); 2021 Sep; 13(18):. PubMed ID: 34572953
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Isolated hepatic perfusion with 200 mg melphalan for advanced noncolorectal liver metastases.
    van Iersel LB; Hoekman EJ; Gelderblom H; Vahrmeijer AL; van Persijn van Meerten EL; Tijl FG; Hartgrink HH; Kuppen PJ; Nortier JW; Tollenaar RA; van de Velde CJ
    Ann Surg Oncol; 2008 Jul; 15(7):1891-8. PubMed ID: 18470571
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Isolated hepatic perfusion for liver metastases of malignant melanoma.
    Rizell M; Mattson J; Cahlin C; Hafström L; Lindner P; Olausson M
    Melanoma Res; 2008 Apr; 18(2):120-6. PubMed ID: 18337648
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Isolated hepatic perfusion with high-dose melphalan results in immediate alterations in tumor gene expression in patients with metastatic ocular melanoma.
    Varghese S; Xu H; Bartlett D; Hughes M; Pingpank JF; Beresnev T; Alexander HR
    Ann Surg Oncol; 2010 Jul; 17(7):1870-7. PubMed ID: 20221901
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combining Hepatic Percutaneous Perfusion with Ipilimumab plus Nivolumab in advanced uveal melanoma (CHOPIN): study protocol for a phase Ib/randomized phase II trial.
    Tong TML; van der Kooij MK; Speetjens FM; van Erkel AR; van der Meer RW; Lutjeboer J; van Persijn van Meerten EL; Martini CH; Zoethout RWM; Tijl FGJ; Blank CU; Burgmans MC; Kapiteijn E
    Trials; 2022 Feb; 23(1):137. PubMed ID: 35152908
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Isolated (hypoxic) hepatic perfusion with high-dose chemotherapy in patients with unresectable liver metastases of uveal melanoma: results from two experienced centres.
    de Leede EM; Burgmans MC; Kapiteijn E; Luyten GP; Jager MJ; Tijl FG; Hartgrink HH; Grünhagen DJ; Rothbarth J; van de Velde CJ; Verhoef C; Vahrmeijer AL
    Melanoma Res; 2016 Dec; 26(6):588-594. PubMed ID: 27513071
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Isolated liver perfusion with melphalan followed by pembrolizumab therapy for unresectable metastases of uveal melanoma to the liver].
    Kaprin AD; Ivanov SA; Unguryan VM; Kazantsev AN; Belov YV
    Khirurgiia (Mosk); 2023; (7):94-99. PubMed ID: 37379411
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chemosaturation with percutaneous hepatic perfusion of melphalan for liver-dominant metastatic uveal melanoma: a single center experience.
    Artzner C; Mossakowski O; Hefferman G; Grosse U; Hoffmann R; Forschner A; Eigentler T; Syha R; Grözinger G
    Cancer Imaging; 2019 May; 19(1):31. PubMed ID: 31146793
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Outcome analysis of a decade-long experience of isolated hepatic perfusion for unresectable liver metastases at a single institution.
    Magge D; Choudry HA; Zeh HJ; Cunningham DE; Steel J; Holtzman MP; Jones HL; Pingpank JF; Bartlett DL; Zureikat AH
    Ann Surg; 2014 May; 259(5):953-9. PubMed ID: 24169176
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.